跳至主要内容
临床试验/ACTRN12615000118505
ACTRN12615000118505
招募中
2 期

Intra-operative administration of dexamethasone intravitreal implants (Ozurdex) versus intravitreal Bevacizumab during cataract surgery for improving visual outcomes in the management of diabetic maculopathy in Central Australia.

Alice Springs Hospital0 个研究点目标入组 40 人2015年2月10日

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
Alice Springs Hospital
入组人数
40
状态
招募中
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2015年2月10日
结束日期
待定
最后更新
6年前
研究类型
Interventional
性别
All

研究者

发起方
Alice Springs Hospital

入排标准

入选标准

  • Adult patients treated by the Central Australian \& Barkly Integrated Eye Health Service, who fit either of the following 2 treatment groups:
  • A. Patients with active DME (defined as macular involving DR, with retinal thickening as assessed on clinical examination), or
  • B. Patients with diabetic retinopathy without active DME
  • \- Participants must have significant lens opacity (more than grade 3 for any type of cataract) and scheduled to undergo cataract surgery at the time of enrolment into the study.
  • \- Participants must have reduced vision (BCVA impaired to at least the level of (6/9\)) in the eye included for the study.

排除标准

  • \- Prior intervention in the affected eye, including intravitreal anti\-VEGF injections within the last 6 weeks, laser within the last 3 months, or Intravitreal triamcinolone within the last 6 months of time of surgery.
  • \- History of open\-angle glaucoma or steroid induced IOP elevation that required IOP\-lowering treatment, or, IOP greater than or equal to 25\.
  • \- Eyes with concurrent ocular pathology other than DME causing visual loss.
  • \- Patients under the age of 18\.

结局指标

主要结局

未指定

相似试验